Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 34 results:
[ Συντάκτης(Desc)] Τίτλος Τύπος Έτος
Φίλτρα: Συντάκτης is Sarafidis, Pantelis A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Sarafidis, P. A., Persu A., Agarwal, iv R., Burnier M., de Leeuw P., Ferro C., et al. (2017).  Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kid. J Hypertens. 35(4), 657-676.
Sarafidis, P. A., Georgianos P. I., & Lasaridis A. N. (2010).  Diuretics in clinical practice. Part II: electrolyte and acid-base disorders complicating diuretic therapy.. Expert Opin Drug Saf. 9(2), 259-73.
Sarafidis, P. A., Loutradis C., Karpetas A., Tzanis G., Bikos A., Raptis V., et al. (2019).  The association of interdialytic blood pressure variability with cardiovascular events and all-cause mortality in haemodialysis patients.. Nephrol Dial Transplant. 34(3), 515-523.
Sarafidis, P. A., & Ruilope L. M. (2013).  Blood pressure targets for patients with chronic kidney disease.. Blood Press. 22(6), 395-6.
Sarafidis, P. A., Georgianos P. I., & Bakris G. L. (2015).  Advances in treatment of hyperkalemia in chronic kidney disease.. Expert Opin Pharmacother. 16(14), 2205-15.
Sarafidis, P. A., Loutradis C., Mayer C. C., Karpetas A., Pagkopoulou E., Bikos A., et al. (2019).  Weak within-individual association of blood pressure and pulse wave velocity in hemodialysis is related to adverse outcomes.. J Hypertens. 37(11), 2200-2208.
Sarafidis, P. A., Georgianos P. I., & Lasaridis A. N. (2011).  PPAR-γ agonism for cardiovascular and renal protection.. Cardiovasc Ther. 29(6), 377-84.
Sarafidis, P. A., & Ruilope L. M. (2014).  The authors reply.. Kidney Int. 86(4), 855.
Sarafidis, P. A., Lazaridis A. A., Ruiz-Hurtado G., & Ruilope L. M. (2017).  Blood pressure reduction in diabetes: lessons from ACCORD, SPRINT and EMPA-REG OUTCOME.. Nat Rev Endocrinol. 13(6), 365-374.
Sarafidis, P. A., Mallamaci F., Loutradis C., Ekart R., Torino C., Karpetas A., et al. (2018).  Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA.. Nephrol Dial Transplant. 33(10), 1872.
Sarafidis, P. A., & Ruilope L. M. (2014).  Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?. Kidney Int. 85(3), 536-46.
Sarafidis, P. A. (2015).  Patient Cases: 1. A Patient with Apparent Compliance.. High Blood Press Cardiovasc Prev. 22 Suppl 1, S15-8.
Sarafidis, P. A., Mallamaci F., Loutradis C., Ekart R., Torino C., Karpetas A., et al. (2019).  Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA.. Nephrol Dial Transplant. 34(9), 1542-1548.
Sarafidis, P. A., & Lasaridis A. N. (2010).  Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy.. Nat Rev Nephrol. 6(8), 447-9.
Sarafidis, P. A., & Bakris G. L. (2014).  Renin inhibition in patients with chronic kidney disease: is it conclusively non-indicated?. J Renin Angiotensin Aldosterone Syst. 15(1), 97-8.
Sarafidis, P. A., Kamperidis V., Loutradis C., Tsilonis K., Mpoutsiouki F., Saratzis A., et al. (2017).  Haemodialysis acutely deteriorates left and right diastolic function and myocardial performance: an effect related to high ultrafiltration volumes?. Nephrol Dial Transplant. 32(8), 1402-1409.
Sarafidis, P. A., Memmos E., Alexandrou M-E., & Papagianni A. (2018).  Mineralocorticoid Receptor Antagonists for Nephroprotection: Current Evidence and Future Perspectives.. Curr Pharm Des. 24(46), 5528-5536.
Sarafidis, P. A., Georgianos P. I., Malindretos P., & Liakopoulos V. (2012).  Pharmacological management of hypertensive emergencies and urgencies: focus on newer agents.. Expert Opin Investig Drugs. 21(8), 1089-106.
Sarafidis, P. A., & Bakris G. L. (2015).  Cardiovascular disease in CKD in 2014: new insights into cardiovascular risk factors and outcomes.. Nat Rev Nephrol. 11(2), 70-2.
Sarafidis, P. A., Ruilope L. M., Loutradis C., Gorostidi M., de la Sierra A., de la Cruz J. J., et al. (2018).  Blood pressure variability increases with advancing chronic kidney disease stage: a cross-sectional analysis of 16 546 hypertensive patients.. J Hypertens. 36(5), 1076-1085.
Sarafidis, P. A., Stafylas P. C., Georgianos P. I., Saratzis A. N., & Lasaridis A. N. (2010).  Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis.. Am J Kidney Dis. 55(5), 835-47.
Sarafidis, P. A., & Bakris G. L. (2014).  Early patterns of blood pressure change and future coronary atherosclerosis.. JAMA. 311(5), 471-2.
Sarafidis, P. A., & Tsapas A. (2016).  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.. N Engl J Med. 374(11), 1092.
Sarafidis, P. A., & Ortiz A. (2020).  The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?. Clin Kidney J. 13(1), 24-26.
Sarafidis, P. A., Georgianos P. I., Germanidis G., Giavroglou C., Nikolaidis P., Lasaridis A. N., et al. (2012).  Hypertension and symptomatic hypokalemia in a patient with simultaneous unilateral stenoses of intrarenal arteries and mesangioproliferative glomerulonephritis.. Am J Kidney Dis. 59(3), 434-8.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές